AM6527 / MAKScientific, Tetra Bio-Pharma - LARVOL DELTA

Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception. (PubMed, Drug Alcohol Depend) - "These results add to a growing body of evidence that CB1 neutral antagonists can attenuate the rewarding properties of opioids while sparing their therapeutically desirable antinociceptive effects, providing support for further investigation of CB1 neutral antagonists as possible treatments for OUD."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Psychiatry • Substance Abuse

Effects of the neutral CB1 receptor antagonist AM6527 on spontaneous, consummatory, and motivated behavior in mice. (PubMed, Psychopharmacology (Berl)) - "Our findings suggest that neutral CB1R antagonism suppresses consummatory and motivated behaviors via potentially dopamine-dependent and -independent mechanisms. By leveraging sub-second behavioral analysis with MoSeq, we further reveal distinct changes in spontaneous behavior, underscoring the relevance of CB-based treatments for maladaptive appetitive and motivational states in both psychiatric and metabolic disorder."

Journal • Preclinical • Metabolic Disorders • Psychiatry

A neutral CB1R antagonist, AM6527, alters spontaneous behavior and suppresses consummatory and motivational responses (Neuroscience 2025) - "Ongoing work is focused on mapping responsive brain regions by assessing c-Fos expression through immunohistochemistry to better understand whether AM6527 engages distinct or overlapping neural circuits during operant and home-cage behaviors. Overall, these results provide new insight into how CB1R signaling shapes motivational output, offering a framework for developing CB-based interventions that selectively modulate appetitive drive."

CNS Disorders • FOS

AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects. (PubMed, Neuropsychopharmacology) - "Together, these findings suggest that AM6527 effectively reduces drug-taking and seeking behaviors without rimonabant-like adverse effects. Thus, AM6527 warrants further investigation as a potential pharmacotherapy for opioid and cocaine use disorders."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry

The neutral CB1 antagonist AM6527 reduces ethanol seeking, binge-like consumption, reinforcing, and withdrawal effects in male and female mice. (PubMed, Psychopharmacology (Berl)) - "Current findings support previous studies with CB1R neutral antagonist in reducing voluntary ethanol intake and seeking behavior. Based on results shown in this work, AM6527 can be developed as a first in class CB1R neutral antagonist to treat AUD in both males and females."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Epilepsy • Mental Retardation • Psychiatry